Journal
ARTHRITIS RESEARCH & THERAPY
Volume 6, Issue 5, Pages 197-202Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/ar1222
Keywords
autoimmune diseases; B cells; BAFF (BLyS); co-stimulation; therapy
Categories
Funding
- NIAID NIH HHS [AI31229, R01 AI047291, AI47291] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI031229, R01AI047291] Funding Source: NIH RePORTER
Ask authors/readers for more resources
It is increasingly recognized that B cells have multiple functions that contribute to the pathogenesis of autoimmunity. Specific targeting of B cells might therefore be an appropriate therapeutic intervention. The tumor necrosis factor-like molecule BAFF (BLyS) is a key B cell survival factor and its receptors are expressed on most peripheral B cells. Several different BAFF antagonists are under development and in early clinical trials. We review here the rationale for BAFF blockade, and its predicted mechanism of action in autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available